EichorEICHOR
Condition: Advanced Sarcoma Synced from ClinicalTrials.gov · August 07, 2026

Recruiting studies: Advanced Sarcoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Phase I Trial of Memory T Cells Expressing an NKG2D Chimeric Antigen Receptor in Children, Adolescents and Young Adult
Phase 1 · 1 location(s) · Antonio Pérez Martínez · NCT06087341A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma
Phase 2 · 2 location(s) · Sarcoma Alliance for Research through Collaboration · NCT06942442Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcom
Phase 2 · 2 location(s) · M.D. Anderson Cancer Center · NCT05019703Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue Sarcomas
Phase 1 · 1 location(s) · Tcelltech Inc. · NCT07052383Cirtuvivint in Selected Advanced Soft-Tissue Sarcomas
Phase 2 · 1 location(s) · Asociación Europea y Latinoamericana SELNET para la Investig · NCT07032285Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06176989Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT05187338Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Phase 1 · 3 location(s) · BioEclipse Therapeutics · NCT04282044A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangement
Phase 1/Phase 2 · 165 location(s) · Turning Point Therapeutics, Inc. · NCT03093116Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Gra
Phase 2 · 22 location(s) · Centre Leon Berard · NCT03624244Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07067255Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma
Phase 2 · 1 location(s) · Gabriel Tinoco · NCT06528769KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC)
Phase 2 · 38 location(s) · Merck Sharp & Dohme LLC · NCT07252739Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Phase 1 · 25 location(s) · Bristol-Myers Squibb · NCT05245500Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Phase 1/Phase 2 · 26 location(s) · Tango Therapeutics, Inc. · NCT05732831MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
Phase 2 · 1 location(s) · HRYZ Biotech Co. · NCT06277154MAGNATE-S: Paclitaxel Polymer Micelles Combo in Advanced Sarcoma
Phase 2 · 1 location(s) · Shanghai 6th People's Hospital · NCT07359053Ivonescimab in the Treatment of Multiple Advanced Tumors
Phase 2 · 1 location(s) · Fudan University · NCT06683846A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Phase 1/Phase 2 · 68 location(s) · Turning Point Therapeutics, Inc. · NCT04094610Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
Phase 1/Phase 2 · 1 location(s) · Memorial Sloan Kettering Cancer Center · NCT04577014T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissu
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT06474676Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT07283731Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04771520Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
Phase 2 · 4 location(s) · Medical College of Wisconsin · NCT04040205A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
Phase 1 · 1 location(s) · GONGCHU Biotechnology Co., Ltd · NCT06508307Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc)
Phase 2 · 11 location(s) · Asociación Europea y Latinoamericana SELNET para la Investig · NCT06114004Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07227571A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional
Phase 1/Phase 2 · 11 location(s) · GI Innovation, Inc. · NCT05824975First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
Phase 1 · 7 location(s) · Daiichi Sankyo · NCT06644755Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Adv
Phase 1 · 16 location(s) · National Cancer Institute (NCI) · NCT05711615
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.